Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Deferred Taxes (2016 - 2025)

Ptc Therapeutics (PTCT) has 5 years of Deferred Taxes data on record, last reported at $1000.0 in Q4 2025.

  • For Q4 2025, Deferred Taxes rose 100.0% year-over-year to $1000.0; the TTM value through Dec 2025 reached -$55.9 million, changed 0.0%, while the annual FY2025 figure was -$3000.0, 99.99% up from the prior year.
  • Deferred Taxes reached $1000.0 in Q4 2025 per PTCT's latest filing, down from $2000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $4.0 million in Q4 2023 and bottomed at -$55.9 million in Q4 2024.
  • Average Deferred Taxes over 3 years is -$10.3 million, with a median of -$1500.0 recorded in 2023.
  • Peak YoY movement for Deferred Taxes: tumbled 1505.13% in 2024, then skyrocketed 300.0% in 2025.
  • A 3-year view of Deferred Taxes shows it stood at $4.0 million in 2023, then crashed by 1505.13% to -$55.9 million in 2024, then soared by 100.0% to $1000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $1000.0 in Q4 2025, $2000.0 in Q1 2025, and -$55.9 million in Q4 2024.